Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease

E. R. Siemers, Joseph Quinn, Jeffrey Kaye, M. R. Farlow, A. Porsteinsson, P. Tariot, P. Zoulnouni, J. E. Galvin, D. M. Holtzman, D. S. Knopman, J. Satterwhite, C. Gonzales, R. A. Dean, P. C. May

Research output: Contribution to journalArticle

270 Citations (Scopus)

Abstract

LY450139 dihydrate, a γ-secretase inhibitor, was studied in a randomized, controlled trial of 70 patients with Alzheimer disease. Subjects were given 30 mg for 1 week followed by 40 mg for 5 weeks. Treatment was well tolerated. Aβ1-40 in plasma decreased by 38.2%; in CSF, Aβ1-40 decreased by 4.42 ± 9.55% (p = not significant). Higher drug doses may result in additional decreases in plasma Aβ concentrations and a measurable decrease in CSF Aβ.

Original languageEnglish (US)
Pages (from-to)602-604
Number of pages3
JournalNeurology
Volume66
Issue number4
DOIs
StatePublished - Feb 2006

Fingerprint

Amyloid Precursor Protein Secretases
N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide
Alzheimer Disease
Randomized Controlled Trials
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease. / Siemers, E. R.; Quinn, Joseph; Kaye, Jeffrey; Farlow, M. R.; Porsteinsson, A.; Tariot, P.; Zoulnouni, P.; Galvin, J. E.; Holtzman, D. M.; Knopman, D. S.; Satterwhite, J.; Gonzales, C.; Dean, R. A.; May, P. C.

In: Neurology, Vol. 66, No. 4, 02.2006, p. 602-604.

Research output: Contribution to journalArticle

Siemers, ER, Quinn, J, Kaye, J, Farlow, MR, Porsteinsson, A, Tariot, P, Zoulnouni, P, Galvin, JE, Holtzman, DM, Knopman, DS, Satterwhite, J, Gonzales, C, Dean, RA & May, PC 2006, 'Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease', Neurology, vol. 66, no. 4, pp. 602-604. https://doi.org/10.1212/01.WNL.0000198762.41312.E1
Siemers, E. R. ; Quinn, Joseph ; Kaye, Jeffrey ; Farlow, M. R. ; Porsteinsson, A. ; Tariot, P. ; Zoulnouni, P. ; Galvin, J. E. ; Holtzman, D. M. ; Knopman, D. S. ; Satterwhite, J. ; Gonzales, C. ; Dean, R. A. ; May, P. C. / Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease. In: Neurology. 2006 ; Vol. 66, No. 4. pp. 602-604.
@article{d1ad511692884c58956dfdef0c50cbfd,
title = "Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease",
abstract = "LY450139 dihydrate, a γ-secretase inhibitor, was studied in a randomized, controlled trial of 70 patients with Alzheimer disease. Subjects were given 30 mg for 1 week followed by 40 mg for 5 weeks. Treatment was well tolerated. Aβ1-40 in plasma decreased by 38.2{\%}; in CSF, Aβ1-40 decreased by 4.42 ± 9.55{\%} (p = not significant). Higher drug doses may result in additional decreases in plasma Aβ concentrations and a measurable decrease in CSF Aβ.",
author = "Siemers, {E. R.} and Joseph Quinn and Jeffrey Kaye and Farlow, {M. R.} and A. Porsteinsson and P. Tariot and P. Zoulnouni and Galvin, {J. E.} and Holtzman, {D. M.} and Knopman, {D. S.} and J. Satterwhite and C. Gonzales and Dean, {R. A.} and May, {P. C.}",
year = "2006",
month = "2",
doi = "10.1212/01.WNL.0000198762.41312.E1",
language = "English (US)",
volume = "66",
pages = "602--604",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease

AU - Siemers, E. R.

AU - Quinn, Joseph

AU - Kaye, Jeffrey

AU - Farlow, M. R.

AU - Porsteinsson, A.

AU - Tariot, P.

AU - Zoulnouni, P.

AU - Galvin, J. E.

AU - Holtzman, D. M.

AU - Knopman, D. S.

AU - Satterwhite, J.

AU - Gonzales, C.

AU - Dean, R. A.

AU - May, P. C.

PY - 2006/2

Y1 - 2006/2

N2 - LY450139 dihydrate, a γ-secretase inhibitor, was studied in a randomized, controlled trial of 70 patients with Alzheimer disease. Subjects were given 30 mg for 1 week followed by 40 mg for 5 weeks. Treatment was well tolerated. Aβ1-40 in plasma decreased by 38.2%; in CSF, Aβ1-40 decreased by 4.42 ± 9.55% (p = not significant). Higher drug doses may result in additional decreases in plasma Aβ concentrations and a measurable decrease in CSF Aβ.

AB - LY450139 dihydrate, a γ-secretase inhibitor, was studied in a randomized, controlled trial of 70 patients with Alzheimer disease. Subjects were given 30 mg for 1 week followed by 40 mg for 5 weeks. Treatment was well tolerated. Aβ1-40 in plasma decreased by 38.2%; in CSF, Aβ1-40 decreased by 4.42 ± 9.55% (p = not significant). Higher drug doses may result in additional decreases in plasma Aβ concentrations and a measurable decrease in CSF Aβ.

UR - http://www.scopus.com/inward/record.url?scp=33645013015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645013015&partnerID=8YFLogxK

U2 - 10.1212/01.WNL.0000198762.41312.E1

DO - 10.1212/01.WNL.0000198762.41312.E1

M3 - Article

VL - 66

SP - 602

EP - 604

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 4

ER -